{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:26:44Z","timestamp":1784586404320,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease is a rare inherited glycosphingolipid storage disorder caused by deleterious mutations in the <jats:italic>GLA<\/jats:italic> gene coding for the lysosomal enzyme \u03b1-galactosidase A. The glucosylceramide synthase inhibitor lucerastat is an iminosugar with potential to provide oral substrate reduction therapy in Fabry disease, regardless of the patient\u00b4s underlying mutation. Since lucerastat exhibits systemic exposure and many patients with Fabry disease suffer from rhythm and conduction abnormalities its effects on cardiac repolarization were evaluated in a thorough QT study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In Part A of this randomized, double-blind, placebo-controlled phase 1 study, single oral doses of 2000 and 4000\u00a0mg lucerastat were investigated to determine the supratherapeutic dose for Part B. The latter was a four-way crossover study to demonstrate that lucerastat at single oral therapeutic and supratherapeutic doses had no effect on the QTc interval\u2009&gt;\u200910\u00a0ms using concentration-QTc modeling as primary analysis. The primary ECG endpoint was placebo-corrected change-from-baseline (\u0394\u0394) in Fridericia-corrected QTc (\u0394\u0394QTcF). Open-label moxifloxacin served as positive control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The effect of lucerastat on \u0394\u0394QTcF was predicted as 0.39\u00a0ms (90% confidence interval [CI]\u2009\u2212\u20090.13 to 0.90) and 1.69\u00a0ms (90% CI 0.33\u20133.05) at lucerastat peak plasma concentration after dosing with 1000\u00a0mg (5.2\u00a0\u00b5g\/mL) and 4000\u00a0mg (24.3\u00a0\u00b5g\/mL), respectively. A QTcF effect\u2009&gt;\u200910\u00a0ms was excluded up to lucerastat plasma concentrations of approximately 34.0\u00a0\u00b5g\/mL. Lucerastat did not exert an effect on other ECG parameters. Across doses, absorption of lucerastat was rapid, its elimination half-life ranged from 8.0 to 10.0\u00a0h, and the pharmacokinetics (PK) of lucerastat were dose-proportional. Moxifloxacin PK were in line with published data and assay sensitivity was demonstrated by the moxifloxacin QTc response. Lucerastat was safe and well tolerated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Lucerastat up to a dose of 4000\u00a0mg has no clinically relevant liability to prolong the QT interval or any clinically relevant effect on other ECG parameters. This will be an important factor in the overall benefit-risk assessment of lucerastat in the potential treatment of Fabry disease.\n<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> The study was registered with the ClinicalTrials.gov identifier NCT03832452 (February 6th, 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03832452\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03832452<\/jats:ext-link>) and the EudraCT number 2018-004546-42 (December 17th, 2018).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01582-7","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T10:04:01Z","timestamp":1603793041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-0375","authenticated-orcid":false,"given":"Markus S.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia N.","family":"Sidharta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Voors-Pette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2016.07.001","volume":"64","author":"R Schiffmann","year":"2016","unstructured":"Schiffmann R, Ries M. Fabry disease: a disorder of childhood onset. Pediatr Neurol. 2016;64:10\u201320. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.07.001.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"1582_CR3","doi-asserted-by":"publisher","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Act Gen Subj. 2020;1864(1):129437. https:\/\/doi.org\/10.1016\/j.bbagen.2019.129437.","journal-title":"Biochim Biophys Act Gen Subj"},{"issue":"4","key":"1582_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2020","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2020;5(4):407\u201313. https:\/\/doi.org\/10.1016\/j.ekir.2019.11.013.","journal-title":"Kidney Int Rep"},{"key":"1582_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00721-4","author":"S Feriozzi","year":"2020","unstructured":"Feriozzi S, Hughes DA. New drugs for the treatment of Anderson-Fabry disease. J Nephrol. 2020. https:\/\/doi.org\/10.1007\/s40620-020-00721-4.","journal-title":"J Nephrol"},{"issue":"3","key":"1582_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","volume":"107","author":"A Pisani","year":"2012","unstructured":"Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, Imbriaco M. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab. 2012;107(3):267\u201375. https:\/\/doi.org\/10.1016\/j.ymgme.2012.08.003.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1582_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543\u201354. https:\/\/doi.org\/10.1007\/s40265-019-01090-4.","journal-title":"Drugs"},{"issue":"1","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364. https:\/\/doi.org\/10.1681\/ASN.2014121226.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589\u201395. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00924.x.","journal-title":"Kidney Int"},{"key":"1582_CR11","unstructured":"European Medicines Agency. Galafold\u00ae (migalastat) 123 mg hard capsules: summary of product characteristics. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004059\/WC500208434.pdf. Accessed 24 April 2020."},{"key":"1582_CR12","unstructured":"United States Food and Drug Administration. Galafold\u00ae (migalastat) capsules for oral use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208623lbl.pdf. Accessed 24 April 2020."},{"issue":"19","key":"1582_CR13","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford RWD, M\u00fchlemann A, Garzotti M, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27(19):3392\u2013403. https:\/\/doi.org\/10.1093\/hmg\/ddy248.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1582_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103(4):703\u201311. https:\/\/doi.org\/10.1002\/cpt.790.","journal-title":"Clin Pharmacol Ther"},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","volume":"12","author":"N Gu\u00e9rard","year":"2017","unstructured":"Gu\u00e9rard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis. 2017;12:9. https:\/\/doi.org\/10.1186\/s13023-017-0565-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/clc.22047","volume":"35","author":"D Acharya","year":"2012","unstructured":"Acharya D, Robertson P, Kay NG, et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35(12):738\u201340. https:\/\/doi.org\/10.1002\/clc.22047.","journal-title":"Clin Cardiol"},{"issue":"7","key":"1582_CR17","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24(7):2102\u201311. https:\/\/doi.org\/10.1093\/ndt\/gfp031.","journal-title":"Nephrol Dial Transpl"},{"key":"1582_CR18","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E14 Guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Step 4. May 12, 2005. https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf. Accessed 24 May 2020."},{"key":"1582_CR19","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E14 Guideline: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions & Answers (R3). December 10, 2015. https:\/\/database.ich.org\/sites\/default\/files\/E14_Q%26As_R3_Q%26As.pdf. Accessed 24 May 2020."},{"issue":"3","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):383\u201397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, et al. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther. 2015;97(4):326\u201335. https:\/\/doi.org\/10.1002\/cpt.60.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/anec.12227","volume":"20","author":"G Ferber","year":"2015","unstructured":"Ferber G, Zhou M, Darpo B. Detection of QTc effects in small studies\u2014implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol. 2015;20(4):368\u201377. https:\/\/doi.org\/10.1111\/anec.12227.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1071\/CH9490149","volume":"2","author":"EJ Williams","year":"1949","unstructured":"Williams EJ. Experimental designs balanced for the estimation of residual effects of treatments. Austr J Sci Res. 1949;2(2):149\u201368. https:\/\/doi.org\/10.1071\/CH9490149.","journal-title":"Austr J Sci Res"},{"issue":"4","key":"1582_CR24","first-page":"401","volume":"18","author":"B Darpo","year":"2011","unstructured":"Darpo B, Fossa AA, Couderc JP, et al. Improving the precision of QT measurements. Cardiol J. 2011;18(4):401\u201310.","journal-title":"Cardiol J"},{"issue":"21","key":"1582_CR25","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","volume":"270","author":"RR Makkar","year":"1993","unstructured":"Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590\u20137.","journal-title":"JAMA"},{"issue":"1","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","volume":"159","author":"B Darpo","year":"2010","unstructured":"Darpo B. The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2010;159(1):49\u201357. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00487.x.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1582_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/10543400802020938","volume":"18","author":"J Zhang","year":"2008","unstructured":"Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT\/QTc studies. J Biopharm Stat. 2008;18(3):451\u201367. https:\/\/doi.org\/10.1080\/10543400802020938.","journal-title":"J Biopharm Stat"},{"issue":"11","key":"1582_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/jcph.944","volume":"57","author":"N Gu\u00e9rard","year":"2017","unstructured":"Gu\u00e9rard N, Zwingelstein C, Dingemanse J. Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment. J Clin Pharmacol. 2017;57(11):1425\u201331. https:\/\/doi.org\/10.1002\/jcph.944.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-019-02808-9","volume":"76","author":"ML Boof","year":"2020","unstructured":"Boof ML, Halabi A, Ufer M, Dingemanse J. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. Eur J Clin Pharmacol. 2020;76(3):431\u20137. https:\/\/doi.org\/10.1007\/s00228-019-02808-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1582_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10543400903581945","volume":"20","author":"LK Yan","year":"2010","unstructured":"Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat. 2010;20(3):497\u2013507. https:\/\/doi.org\/10.1080\/10543400903581945.","journal-title":"J Biopharm Stat"},{"issue":"8","key":"1582_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0091270010381498","volume":"51","author":"JA Florian","year":"2011","unstructured":"Florian JA, Torn\u00f8e CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011;51(8):1152\u201362. https:\/\/doi.org\/10.1177\/0091270010381498.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1582_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bcp.12168","volume":"77","author":"J Taubel","year":"2013","unstructured":"Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2013;77(1):170\u20139. https:\/\/doi.org\/10.1111\/bcp.12168.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1582_CR33","first-page":"272","volume":"8","author":"J T\u00e4ubel","year":"2016","unstructured":"T\u00e4ubel J, Ferber G, Fernandes S, Lorch U, Sust M, Camm AJ. The effects of a meal on QTc to demonstrate ECG assay sensitivity in phase I studies. J Bioequiv Bioavailab. 2016;8(6):272\u20133.","journal-title":"J Bioequiv Bioavailab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01582-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:27:34Z","timestamp":1635290854000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01582-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01582-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"14 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Committee (Medisch Ethische Toetsings Commissie, Assen, The Netherlands). Written informed consent was obtained from each subject prior to enrolment in the study, which was conducted at QPS Netherlands B.V. (Groningen, The Netherlands), in accordance with the revised Declaration of Helsinki principles, International Council for Harmonization Good Clinical Practice guidelines, and applicable laws and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Idorsia Pharmaceuticals Ltd (Allschwil, Switzerland) sponsored this study. All authors had support from Idorsia for the submitted work; MSM, PNS, and JD are full-time employees of Idorsia and owners of stock units and\/or restricted stock units from Idorsia. CV-P is a full-time employee of the clinical research organization QPS Netherlands B.V. (Groningen, The Netherlands) contracted to conduct the study; no other competing interests have been raised. HX is a full-time employee of the ECG service provider eResearch Technology Inc. (ERT\u00ae, Rochester, NY, USA) contracted for the evaluation of cardiac safety and statistical analysis of Holter ECG data; BD is a consultant for ERT\u00ae and owns stock and is eligible for stock options in the company. No other competing interests have been raised.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}